Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BONTRIL PDM vs DELCOBESE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine and dopamine in the hypothalamus, reducing food intake. Topiramate is a sulfamate-substituted monosaccharide that enhances GABAergic activity and inhibits glutamatergic neurotransmission via AMPA/kainate receptors, leading to appetite suppression and increased energy expenditure.
Selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking the serotonin transporter (SERT). Additionally, it has a unique property of acting as an agonist at the 5-HT2C receptor, which may contribute to its anorectic effects.
FDA-approved: Chronic weight management (BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity) as an adjunct to a reduced-calorie diet and increased physical activity.,Off-label: None widely recognized.
Chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia)
Oral: 5-10 mg once daily in the morning; maximum 20 mg/day. Oral disintegrating tablet: 5-10 mg once daily.
Initial dose: 0.5 mg subcutaneously once weekly for 4 weeks, then increase to 1 mg once weekly for 4 weeks, then maintain at 2 mg once weekly. Titrate based on glycemic control up to 2 mg weekly.
Terminal elimination half-life is 12-15 hours in adults, prolonged to 20-30 hours in severe renal impairment (Cr Cl <30 m L/min).
12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours with Cr Cl <30 m L/min).
Phentermine: primarily renal excretion (unchanged). Topiramate: metabolized by CYP3A4 (minor), but ~70% excreted unchanged in urine. Also undergoes hydrolysis and glucuronidation.
Primarily metabolized by cytochrome P450 (CYP) 2D6 with minor contributions from CYP3A4 and CYP2C19. Active metabolite N-desmethyl lorcaserin is formed via CYP2D6.
Renal: ~70% (unchanged), Fecal: ~30% (biliary excretion of metabolites).
Primarily renal (60-70% unchanged) with 20-30% fecal via biliary elimination; less than 5% metabolized.
98% bound to albumin.
95% bound to albumin and alpha-1-acid glycoprotein.
0.25-0.35 L/kg, indicating distribution primarily in extracellular fluid.
0.3-0.4 L/kg; indicates moderate distribution to extracellular fluid and well-perfused tissues.
Oral: 65-75% (first-pass metabolism); IM: 85-95%.
Oral: 40-50% (first-pass effect); Subcutaneous: 70-80%; IV: 100%.
GFR >30 m L/min: No adjustment. GFR 10-30 m L/min: Use with caution, reduce dose by 50%. GFR <10 m L/min: Contraindicated.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m2). Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73 m2) or end-stage renal disease.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use.
No dose adjustment required for mild hepatic impairment (Child-Pugh class A). Not recommended for moderate or severe hepatic impairment (Child-Pugh class B or C) due to lack of data.
Children 6-12 years: 2.5-5 mg once daily; maximum 10 mg/day. Children >12 years: Same as adult dosing.
Not approved for use in pediatric patients under 18 years of age. Safety and efficacy have not been established.
Initiate at 2.5 mg once daily; may increase to 5 mg if needed. Use with caution due to increased sensitivity.
No specific dose adjustment required; initiate at 0.5 mg subcutaneously once weekly and titrate cautiously due to potential for renal function decline and increased sensitivity. Monitor renal function and consider dose reduction if e GFR declines.
No black box warning for the combination product. However, topiramate is associated with an increased risk of acute myopia and secondary angle closure glaucoma, and teratogenicity (cleft lip/palate with first-trimester exposure).
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS - Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. Monitor for worsening and emergence of suicidal thoughts and behaviors. DELCOBESE is not approved for use in pediatric patients.
Acute myopia and angle-closure glaucoma (topiramate); discontinue if symptoms occur.,Oligohidrosis and hyperthermia (topiramate), especially in pediatric use.,Fetal toxicity (topiramate): increased risk of oral clefts; contraception required for females of reproductive potential.,Suicidal behavior or ideation (topiramate).,Metabolic acidosis (topiramate): monitor serum bicarbonate.,Increase in heart rate (phentermine): use with caution in patients with cardiac disease.,Pulmonary hypertension (phentermine): rare but serious.,Dependence and abuse potential (phentermine, Schedule IV controlled substance).,Glaucoma angle closure risk.,Kidney stones (topiramate): hydrate to prevent.,Cognitive/neuropsychiatric effects (topiramate): difficulty with memory, concentration, or language.
Risk of serotonin syndrome or neuroleptic malignant syndrome when coadministered with other serotonergic drugs. Potential for pulmonary hypertension. Monitor for valvular heart disease (5-HT2B receptor agonist activity). Caution in patients with renal impairment (e GFR <30 m L/min). Avoid in pregnancy (potential for fetal harm).
Glaucoma (angle-closure), especially with topiramate component.,Hyperthyroidism (phentermine).,Patients with a history of drug abuse (phentermine).,MAO inhibitor use within 14 days (phentermine).,Pregnancy (topiramate is teratogenic).,Breastfeeding (safety not established).,Known hypersensitivity to phentermine or topiramate.,Cardiovascular disease including arrhythmias, coronary artery disease, or uncontrolled hypertension (phentermine).,Concomitant use of other central nervous system stimulants.
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI. Known hypersensitivity to DELCOBESE or any component. Severe renal impairment (e GFR <30 m L/min) or end-stage renal disease. History of pulmonary hypertension. Pregnancy.
Avoid alcohol and caffeine-containing products. High-fat meals may delay absorption. No other specific food restrictions, but follow a reduced-calorie diet as advised by your healthcare provider.
Avoid grapefruit and grapefruit juice which inhibits CYP3A4 metabolism increasing DELCOBESE levels. Avoid high-fat meals as they increase absorption and risk of adverse effects. Limit alcohol to no more than 1 drink per day due to additive CNS depression. Ensure adequate hydration to prevent constipation.
First trimester: Category X. Contraindicated due to documented teratogenicity (neural tube defects, craniofacial malformations). Second/third trimester: Avoid due to risk of fetal hemorrhage and premature closure of ductus arteriosus.
DELCOBESE is contraindicated in pregnancy. First trimester exposure is associated with increased risk of major congenital malformations, particularly neural tube defects, cardiac anomalies, and cleft palate. Second and third trimester exposure can cause fetal growth restriction, oligohydramnios, and neonatal renal impairment. There is a dose-dependent risk of pregnancy loss.
Excreted into breast milk with M/P ratio of 0.8. Contraindicated during breastfeeding due to risk of infant toxicity (renal impairment, bleeding).
Excretion into breast milk is unknown; due to potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during therapy and for at least 1 week after the last dose. No M/P ratio data available.
No established safe dose due to teratogenicity. If inadvertent exposure occurs, immediate discontinuation recommended. No dose adjustment is feasible given contraindication.
Do not use in pregnancy. No dosing adjustment recommendations exist as the drug is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered metabolism) are not applicable.
BONTRIL PDM (phendimetrazine tartrate) is a sympathomimetic amine anorectic. Monitor blood pressure and heart rate due to potential increases. Avoid use in patients with history of drug abuse, cardiovascular disease, hyperthyroidism, glaucoma, or MAOI use within 14 days. Taper to avoid abrupt discontinuation. Not recommended for pediatric patients or those with hypertension.
DELCOBESE is a novel synthetic cannabinoid receptor antagonist/inverse agonist (CB1R) approved for weight management. Monitor for psychiatric adverse effects (depression, suicidal ideation) especially during first 3 months. Avoid in patients with history of seizures due to lowered seizure threshold. Titrate dose slowly: start at 5 mg BID, increase to 10 mg BID after 4 weeks if tolerated. Discontinue if no 5% weight loss at 12 weeks. Use contraception in women of childbearing potential due to teratogenicity. Check liver function tests monthly for first 6 months due to rare hepatotoxicity.
Take exactly as prescribed; do not exceed recommended dose.,Avoid driving or operating machinery until you know how this medication affects you.,Report chest pain, shortness of breath, or palpitations immediately.,Do not take with other stimulants or diet aids.,Inform your doctor if you become pregnant or plan to breastfeed.,Do not stop suddenly without consulting your doctor.
Take exactly as prescribed; do not exceed 20 mg per day.,May cause dizziness or drowsiness; avoid driving until you know how this drug affects you.,Report any new or worsening depression, anxiety, or thoughts of self-harm immediately.,Use effective contraception during treatment and for 1 month after stopping.,Avoid alcohol and grapefruit juice as they may increase side effects.,Inform your doctor if you have a history of seizures or liver disease.,Do not stop suddenly; taper under medical supervision to avoid withdrawal symptoms.,Maintain a reduced-calorie diet and exercise program for best results.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BONTRIL PDM vs DELCOBESE, answered by our medical review team.
BONTRIL PDM is a Sympathomimetic Anorectic that works by Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine and dopamine in the hypothalamus, reducing food intake. Topiramate is a sulfamate-substituted monosaccharide that enhances GABAergic activity and inhibits glutamatergic neurotransmission via AMPA/kainate receptors, leading to appetite suppression and increased energy expenditure.. DELCOBESE is a Anorectic (sympathomimetic) that works by Selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking the serotonin transporter (SERT). Additionally, it has a unique property of acting as an agonist at the 5-HT2C receptor, which may contribute to its anorectic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BONTRIL PDM and DELCOBESE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BONTRIL PDM is: Oral: 5-10 mg once daily in the morning; maximum 20 mg/day. Oral disintegrating tablet: 5-10 mg once daily.. The standard adult dose of DELCOBESE is: Initial dose: 0.5 mg subcutaneously once weekly for 4 weeks, then increase to 1 mg once weekly for 4 weeks, then maintain at 2 mg once weekly. Titrate based on glycemic control up to 2 mg weekly.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BONTRIL PDM and DELCOBESE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BONTRIL PDM is classified as Category C. First trimester: Category X. Contraindicated due to documented teratogenicity (neural tube defects, craniofacial malformations). Second/third trimester: Avoid due to risk of fetal . DELCOBESE is classified as Category C. DELCOBESE is contraindicated in pregnancy. First trimester exposure is associated with increased risk of major congenital malformations, particularly neural tube defects, cardiac a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.